I ron is an essential trace element that plays a role in oxygen transport, cellular respiration, immune system regulation, and protein transcription. [1] [2] [3] [4] Functional iron deficiency occurs when iron stores are trapped inside cells of the reticuloendothelial system, reducing iron availability to target tissues and organs, despite adequate iron stores in the body. Although absolute iron deficiency is uncommon in patients with heart failure, functional iron deficiency, mediated by activation of proinflammatory cytokines in heart failure, may be much more common and may reduce functional capacity by decreasing iron-dependent oxygen transport and oxidative phosphorylation in skeletal muscle. 5, 6 
Clinical Perspective on p 606
Iron deficiency is a potential therapeutic target in heart failure. Several small single-center studies have reported that parenteral repletion of iron in heart failure patients with iron deficiency anemia improves exercise capacity and quality of life. 7-10 A larger multicenter trial demonstrated that parental repletion of iron in heart failure patients with functional iron deficiency improved exercise capacity and quality of life, independent of the presence of anemia. 11 Functional iron deficiency has also been reported to be associated with increased mortality risk, independent of the presence of anemia, in patients with advanced systolic heart failure referred to specialized care centers. 6 Whether iron deficiency is an independent predictor of mortality in community-dwelling heart failure patients is unknown.
Accordingly, we sought to characterize the prevalence, clinical correlates, and independent prognostic significance of iron deficiency in a representative sample of US civilian noninstitutionalized adults with self-reported heart failure who participated in the Third National Health and Nutrition Examination Survey (NHANES) III survey.
Methods

Study Design and Sample
This is a prospective cohort study of adults with self-reported heart failure in NHANES III. 12 Baseline data were collected from 1988 to 1994 as a cross-sectional, complex, multistage survey of a representative sample of the US civilian noninstitutionalized population. NHANES III oversampled non-Hispanic blacks, Mexican Americans, and persons over the age of 60 years to obtain reliable information about these subgroups. Individuals Ն17 years of age (nϭ20 050) received a home-based interview; 17 705 of these participants were examined in the mobile examination center (MEC). Follow-up on vital status and cause of death were obtained from the NHANES III Linked Mortality File, which linked participants to information obtained from death certificate data in the National Death Index. 13 Responses to demographic, lifestyle, dietary, and medical history questions were gathered by trained professionals during the household and MEC surveys. During the MEC examination, a physical examination was performed and blood was drawn. We included participants Ն17 years of age who were examined in the MEC and who identified themselves as having heart failure by a "yes" response to the question "Has a doctor ever told you that you had congestive heart failure?" Iron deficiency was defined in both absolute and functional terms; it included participants with a ferritin level Ͻ100 g/L or between 100 and 299 g/L if the transferrin saturation was Ͻ20%. 11
Sample Demographics, Cardiovascular Risk Factors, and Comorbid Conditions
We obtained information on age, sex, race-ethnicity, education, and income from the NHANES III household adult survey data. Race-ethnicity was self-reported and classified as non-Hispanic white, non-Hispanic black, Mexican American, and other. Education was categorized as did not complete high school, completed high school only, or obtained at least some higher education. Poverty income ratio, the ratio between the midpoint of the observed family income category (Ͻ$10 000, $10 000 to $29 999, $30 000 to 49 999, and Ն$50 000) and the poverty threshold produced annually by the Census Bureau, allowed income to be analyzed uniformly across the entire survey period.
Smoking status was dichotomized as current smokers and former or never-smokers. Body mass index (BMI) was calculated from height and weight measured at the MEC examination. It was analyzed as both a continuous variable and as a categorical variable dichotomized into obese (BMI Ն30 kg/m 2 ) and nonobese (BMI Ͻ30 kg/m 2 ). 14 Physical activity was classified as vigorous, moderate, light, or sedentary from the frequency and intensity of leisure time exercise. 15 Blood pressures were measured in the interview by a trained interviewer and in the MEC examination by a physician, and an average of up to 6 values for systolic and diastolic blood pressures were recorded. Hypertension was defined by self-reported diagnosis, self-reported antihypertensive medication use, mean systolic blood pressure Ն140 mm Hg, or mean diastolic blood pressure Ն90 mm Hg. Total cholesterol (mg/dL), triglyceride (mg/dL), high-density lipoprotein (mg/dL), C-reactive protein (CRP, mg/dL), ferritin (g/L), transferrin saturation (%), hemoglobin (g/dL), hemoglobin A1c (HbA1c, %), sodium (mmol/L), and creatinine (mg/dL) levels were obtained from blood collected during the MEC examination using methods described by the US Department of Health and Human Services. 16 Ferritin was measured by using Bio-Rad Laboratories Quantimune Ferritin Immunoradiometric Assay kit, which was a single-incubation, 2-site assay using a radiolabeled I-125 antibody to ferritin. Not all participants had low-density lipoprotein measurements, and as such low-density lipoprotein was not included in the analysis.
Hyperlipidemia was defined by self-reported high cholesterol, self-reported cholesterol-lowering medication use, or total cholesterol Ն200 mg/dL. Diabetes was defined by self report or baseline HbA1c measurement Ն7% on MEC examination. Anemia was defined as hemoglobin Ͻ12.5 g/dL. Diagnoses of other comorbid conditions such as myocardial infarction and cancer were obtained by self-report. Neither B-type natriuretic peptide (BNP) nor N-terminal pro-B-type natriuretic peptide (NT-proBNP) were measured in NHANES III.
Outcome Variables
Person-months of follow-up from the MEC examination date were obtained from the Linked Mortality File. Mortality follow-up was complete through December 31, 2000, with the exception of 1 participant who was lost to follow-up. All-cause mortality was defined by the final determination of vital status by the National Center for Health Statistics, using a probabilistic match between NHANES III and National Death Index death certificate data. Cardiovascular mortality was determined from the death certificate data by pooling cause of death codes from the 10th revision of the International Classification of Diseases, Injuries, and Causes of Death (ICD-10). 17 Cardiovascular disease mortality included codes for deaths from all major cardiovascular diseases (ICD-10 codes I00-I78), including ischemic heart disease, stroke, and other cardiovascular disorders.
Statistical Analysis
Among participants with self-reported heart failure, baseline characteristics, cardiovascular risk factors, and comorbid conditions were compared between participants with iron deficiency and those without iron deficiency, using survey procedures in SAS 9.2 (Statistical Analysis System, Cary, NC). 18 Unadjusted all-cause and cardiovascular mortality rates stratified by the presence or absence of iron deficiency along with probability values were obtained by a life-table product-limit method. Kaplan-Meier curves for both all-cause and cardiovascular mortality were determined for the dichotomous iron deficiency variable and the equality of curves was tested by a log-rank statistic. To evaluate the association between iron deficiency and mortality, we fit age-and sex-adjusted Cox proportional hazards models. Similarly, we fit age-and sex-adjusted Cox proportional hazards models for 1 g/dL decreases in hemoglobin, 1 mg/dL increases in CRP, 25 g/L decreases in ferritin, and 1% decreases in transferrin saturation. Two-sided probability values Ͻ0.05 were considered significant. The final multivariate Cox proportional hazards models for iron deficiency included age, sex, hemoglobin, CRP, BMI, and self-reported myocardial infarction.
The complex sample survey design of NHANES III included stratification, clustering, and unequal weighting of participants to estimate characteristics for the entire population. To account for this complex survey design, we used survey procedures (Proc Surveymeans, Proc Surveyfreq, Proc Surveyreg, and Proc Surveyphreg) in SAS that allowed us to incorporate these in the analysis. 18, 19 Specifically, a strata statement was used to account for the stratified nature of the sampling procedure in NHANES III. Because NHANES III also used cluster sampling to group together sampling units, we included a cluster statement in the survey procedures. Finally, to provide accurate population-based estimates, participants in NHANES III were weighted unequally in the survey design to better represent the target population. This was accounted for by using a weight statement in the final survey procedures. 20 All of the survey weights, strata, and cluster variables were provided in the NHANES III database and linked to each individual participant.
Results
There were 574 participants with self-reported heart failure and available laboratory studies. Iron deficiency was present in 352 participants (61.3%). Anemia was present in 96 participants (16.7%). Iron deficiency was more common in participants with anemia compared with those without anemia (73.2% versus 56.4%, Pϭ0.05). Participants with iron deficiency were more likely to be anemic than participants without iron deficiency (20.2% versus 10.7%, Pϭ0.06). Participants with iron deficiency were more likely to be female (60.1% versus 34.9%, PϽ0.001), less likely to be obese (29.0% versus 41.8%, Pϭ0.01), and less likely to self-report a history of myocardial infarction (50.2% versus 65.0%, Pϭ0.03) than participants without iron deficiency. Iron deficiency was associated with lower mean hemoglobin (13.6 versus 14.2 g/dL, Pϭ0.007) and higher mean CRP (0.95 versus 0.63 mg/dL, Pϭ0.04) ( Table 1) .
Of the 574 participants with heart failure, 273 (47.6%) were alive through the follow-up period and 300 (52.3%) Continuous variables are given as means; categorical variables are given as percentages. Ninety-five percent confidence intervals are given in parentheses. Data are reported as population estimates, using survey weights, strata, and cluster variables. The first column reports data for the entire heart failure population; the remaining columns report data stratified by presence or absence of iron deficiency.
died, 193 (33.6%) from cardiovascular causes. One participant was lost to follow-up. Mean follow up time was 6.7 (6.2 to 7.2) years. Unadjusted mortality rates in participants with and without iron deficiency did not differ ( Table 2 and Figures 1 and 2) .
To further evaluate the association between iron deficiency and mortality while controlling for important confounders, Cox proportional hazards models were used; relative risks were reported as hazard ratios with 95% confidence intervals ( HF indicates heart failure; ID, iron deficiency. *All-cause and cardiovascular deaths are presented as the total number of deaths as well as the percentage of participants deceased on follow-up. The first column reports data for the entire cohort of participants with heart failure; the remaining columns report data stratified by presence or absence of iron deficiency.
†Population estimates of the percentage of participants deceased on follow-up are reported using survey weights, strata, and cluster variables. Ninety-five percent confidence intervals for these population estimates are given in parentheses.
‡Mortality rates per 1000 person-years of follow-up are presented unadjusted for confounders. Data are reported as population estimates using survey weights, strata, and cluster variables. .01] mortality. The estimate of the association between transferrin saturation and mortality was not longer significant both for all causes and for cardiovascular causes. In the age-and sex-adjusted models and the multivariate models, iron deficiency was not associated with all-cause or cardiovascular mortality.
Finally we tested the prognostic significance of more restrictive definitions of iron deficiency, analyzing low ferritin levels independent of transferrin saturation levels; 9.8% of the participants had a ferritin level Ͻ30 g/L, whereas 47.2% of the participants had a ferritin level Ͻ100 g/L. 
Discussion
This population-based study demonstrates that iron deficiency is common in adults with self-reported heart failure. 6 This study also confirmed that decreases in hemoglobin are associated with increased cardiovascular mortality in adults with self-reported heart failure, 5, [21] [22] [23] [24] [25] [26] though this association did not remain statistically significant for all-cause mortality in the multivariate model. This study also confirmed the association of CRP with increased mortality in adults with self-reported heart failure, [27] [28] [29] [30] an association that remained significant in the multivariate model. This study demonstrated cross-sectional associations between functional iron deficiency and both anemia and inflammation, findings that are consistent with the putative pathophysiology of iron deficiency in heart failure. 1, 26, [31] [32] [33] Contrary to the findings of a recently published observational study, 6 we did not observe a significant association between iron deficiency and all-cause or cardiovascular mortality in community-dwelling adults with self-reported heart failure.
Proposed mechanisms for anemia in heart failure include insufficient erythropoietin secretion (due in part to inhibition of the renin-angiotensin system), erythropoietin resistance (due to chronic inflammation), hemodilution, comorbid kidney disease, and iron deficiency. 1 Iron deficiency in and of itself may also be multifactorial, though inflamma- CRP indicates C-reactive protein; BMI, body mass index.
The multivariate predictors used in the Cox models included age, sex, hemoglobin, CRP, BMI (as a continuous variable), and iron deficiency. In the Cox models for ferritin and transferrin saturation, iron deficiency was excluded from the multivariate models (as it was defined using these variables) but the remaining predictors were included. All hazard ratios and confidence intervals incorporated survey weights, strata, and cluster variables to obtain population estimates. The hazard ratios presented above reflect 1 g/dL decreases in hemoglobin, 1 mg/dL increases in CRP, 1 kg/m 2 -increases in BMI, 25 g/L decreases in ferritin, and 1% decreases in transferrin saturation. Iron deficiency is a categorical variable.
tion appears to be one of the key mediators of iron deficiency and the subsequent progression to anemia in heart failure. 1, 34 Proinflammatory cytokines have been shown to lead to decreased intestinal absorption of iron and sequestration of iron in macrophages. 34 The mechanism is related to that observed in anemia of chronic disease. 35 CRP is an inflammatory marker that is known to be elevated in heart failure and carries prognostic significance [27] [28] [29] [30] ; in addition CRP demonstrates an inverse relationship to hemoglobin. 36 The effects of chronic inflammation and iron deficiency may be detrimental before the onset of full-blown anemia, as iron deficiency in and of itself is associated with decreased aerobic capacity and abnormal oxygen transport in skeletal muscle, independent of the presence of anemia. 1 Our research supports the hypothesis that inflammation mediates the link between iron deficiency and anemia because participants with iron deficiency tended to have higher average CRP levels and lower hemoglobin levels, with nearly double the risk of full-blown anemia.
Our study had several important limitations. Our observational, prospective study design does not fully allow causal inference because unmeasured confounders or other biases may have contributed to our results. NHANES III did not collect data on BNP or NT-proBNP; as such, we were unable to use this value as a corroborator of volume status in our cohort. We also did not have data available on medications used by the participants in the study; as such, we were unable to determine if participants were taking medications with proven efficacy in heart failure. Other than the observed high event rate, the available data did not allow us to objectively substantiate the diagnosis of heart failure. Because the diagnosis of heart failure was obtained by self-report, it may be subject to self-report biases. However, the event rates were consistent with a mild heart failure population, as several recent studies have noted an annual mortality for class I-II heart failure around 5% to 7%. 37, 38 Given that our data were collected from a representative sample of the US civilian noninstitutionalized population, it is plausible that these were mostly highly functional and ambulatory patients with less advanced disease and survival comparable to the recently studied mild heart failure populations. Compared with the results presented by Jankowska et al 6 in patients with advanced systolic heart failure referred to tertiary heart failure treatment centers, our participant pool may have been healthier overall. This is supported by the fact that our population had a lower mean CRP, higher mean BMI, and lower frequency of diabetes and myocardial infarction compared with the population studied by Jankowska et al. In addition, the relatively high mean systolic blood pressure, large proportion of women, and age of the population indicated that many of our participants had preserved ejection fraction. As such, it is possible that iron deficiency may not fully retain its prognostic value in healthier heart failure patients with varying degrees of systolic function. This appears to be consistent with the finding by Jankowska et al that functional iron deficiency is associated with higher New York Heart Association (NYHA) functional class; as such, iron deficiency may have a higher prognostic significance in patients falling into higher NYHA functional classes than the ambulatory, community-dwelling participants in this study.
The present analysis also has several important strengths. First, this is the first study looking at the prevalence of iron deficiency specifically in a communitydwelling population of US adults with self-reported heart failure. Second, a population-based representative sample was surveyed, allowing estimates of usually underrepresented groups such as minorities and the elderly. Third, data were collected using a standardized, detailed, laborintensive process with rigorous quality control. Fourth, because data were collected in a nonmedical setting for research purposes, there was little missing data and less chance of subject response bias. Fifth, because subjects were randomly selected from different geographic regions across the country, these results are potentially generalizable to the entire US population of community-dwelling adults with heart failure. Last, the use of a hard end point such as all-cause mortality as the primary outcome variable reduces the likelihood of spurious results.
Though there is evidence that parental repletion of iron in heart failure patients with functional iron deficiency independent of the presence of anemia improves exercise capacity and quality of life, 11 there is also evidence that moderately increased iron stores without overt evidence of organ dysfunction may be associated with an increased risk of cardiovascular events. 39 This association may in part be explained by the iron-dependent formation of free hydroxyl radicals that can damage cells irreversibly and promote reperfusion injury, leading to possible relationships between iron overload and carcinogenesis and atherogenesis. 39 -40 Blood donation is known to deplete total body iron stores and is associated with reduced cardiovascular risk in blood donor populations. [41] [42] [43] [44] Currently available biomarkers of iron stores provide limited information on tissue iron stores and regulation of intracellular iron stores. These limitations may have led to misclassification of the true iron storage status in our population and obscured our ability to detect a difference in mortality between the groups with and without iron deficiency. An ongoing prospective study of the effects of parenteral iron therapy on clinical outcomes in the heart failure population will provide important additional data to assess the potential causal role of iron in disease progression.
In conclusion, iron deficiency is common in communitydwelling adults with heart failure and is associated with markers of anemia and inflammation. Our data do not support a direct relationship between iron deficiency and mortality in community-dwelling US adults with selfreported heart failure. Further work is needed to determine the long-term effects of iron therapy in the heart failure population.
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